Macular degeneration

FILE- In this April 28, 2017 file photo, Dr. Salomon Melgen arrives at the federal courthouse in West Palm Beach, Fla. Prosecutors say Melgen, a prominent Florida eye doctor who was accused of bribing New Jersey Democratic Sen. Bob Menendez, should get a 30-year sentence for Medicare fraud. A three-day sentencing hearing for Melgen is scheduled to begin Tuesday, Dec. 5, 2017, in West Palm Beach on 67 counts. Prosecutors say the 63-year-old doctor stole more than $100 million from the federal government. He was convicted in April after a 2 1/2- month trial.(Lannis Water/Palm Beach Post via AP, File)
December 07, 2017 - 5:03 pm
WEST PALM BEACH, Fla. (AP) — Evidence proves a politically connected Florida eye doctor convicted of Medicare fraud stole $136 million, prosecutors insisted on Thursday, countering a defense argument that the fraud added up to just $64,000. Assistant U.S. Attorney Alexandra Chase said Dr. Salomon...
Read More
This image provided by the National Eye Institute shows a microscopic image of a retina being damaged by the so-called “dry” form of age-related macular degeneration. An experimental drug is showing promise against an eye disease that blinds older adults. Age-related macular degeneration gradually erodes seniors’ central vision, making it difficult to read or see faces. (National Eye Institute via AP)
June 22, 2017 - 3:21 am
WASHINGTON (AP) — An experimental drug is showing promise against an untreatable eye disease that blinds older adults — and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision. Age-related macular degeneration, or AMD, is the leading...
Read More
This image provided by the National Eye Institute shows a microscopic image of a retina being damaged by the so-called “dry” form of age-related macular degeneration. An experimental drug is showing promise against an eye disease that blinds older adults. Age-related macular degeneration gradually erodes seniors’ central vision, making it difficult to read or see faces. (National Eye Institute via AP)
June 21, 2017 - 5:30 pm
WASHINGTON (AP) — An experimental drug is showing promise against an untreatable eye disease that blinds older adults — and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision. Age-related macular degeneration, or AMD, is the leading...
Read More
This image provided by the National Eye Institute shows a microscopic image of a retina being damaged by the so-called “dry” form of age-related macular degeneration. An experimental drug is showing promise against an eye disease that blinds older adults. Age-related macular degeneration gradually erodes seniors’ central vision, making it difficult to read or see faces. (National Eye Institute via AP)
June 21, 2017 - 3:26 pm
WASHINGTON (AP) — An experimental drug is showing promise against an untreatable eye disease that blinds older adults — and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision. Age-related macular degeneration, or AMD, is the leading...
Read More
This image provided by the National Eye Institute shows a microscopic image of a retina being damaged by the so-called “dry” form of age-related macular degeneration. An experimental drug is showing promise against an eye disease that blinds older adults. Age-related macular degeneration gradually erodes seniors’ central vision, making it difficult to read or see faces. (National Eye Institute via AP)
June 21, 2017 - 2:30 pm
WASHINGTON (AP) — An experimental drug is showing promise against an untreatable eye disease that blinds older adults — and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision. Age-related macular degeneration, or AMD, is the leading...
Read More